James Foord Investing Group Leader
Summary
Rocket Lab Corporation is a Strong Buy with a $100 target; the Neutron delay is known, while the underlying business is improving.
RKLB's backlog reached $3.57 billion, up 52% sequentially, with Neutron demand and pricing strengthening despite the launch delay into 2027.
Q3 revenue rose 73% to $267.8 million, operating cash flow turned positive, and management expects EBITDA profitability within six months of a successful Neutron flight.
At 44x estimated 2026 sales, RKLB remains expensive; further Neutron delays, negative free cash flow and Iridium approval present risks. Leave room to add on dips.
This idea was discussed in more depth with members of my private investing community, The Pragmatic Investor. Learn More »
Black Friday Sale 2026: Get 20% Off
Infinite Creations/iStock via Getty Images
Thesis Summary
Rocket Lab Corporation (RKLB) has had a rough year.…